The first patient included in Japan in Isofol's Phase 3 AGENT study
GOTHENBURG, Sweden, February 18 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL) today announced that the first patient in Japan has initiated treatment in the global Phase 3 AGENT study.Isofol’s drug candidate arfolitixorin is being evaluated in the first line of treatment of metastatic colorectal cancer (mCRC). The study is currently being conducted in the USA, Canada, Europe, Australia and now also in Japan. Isofol plans to start the trial in up to 15 clinics in Japan, in addition to the 80 clinics that are already open. “A high pace is kept in our patient